Clinical and laboratory findings of the patients with Sjögren’s syndrome
| Characteristics | Pilocarpine (n = 29) | Artificial tears (n = 28) | Lachrymal puncta occlusion (n = 28) | p Values |
|---|---|---|---|---|
| Results are shown as No (%) unless stated otherwise. | ||||
| *Extraglandular manifestations = Raynaud’s phenomenon, arthralgias or/and arthritis, lymphadenopathy, hepatomegaly. | ||||
| NS, non-significant; IgM RF, IgM rheumatoid factor; ANA, antinuclear antibodies; Ro (SSA) and La (SSB), antibodies to extractable nuclear antigens. | ||||
| Age (years), mean (SD) | 57.0 (11.5) | 59.9 (9.9) | 57.8 (12.9) | NS |
| Disease durations (years), mean (SD) | 10.5 (6.1) | 11.2 (5.0) | 10.5 (5.4) | NS |
| Dry eyes | 29 (100) | 29 (100) | 29 (100) | NS |
| Dry mouth | 24 (83) | 25 (86) | 26 (90) | NS |
| Parotid gland enlargement | 6 (21) | 5 (17) | 6 (21) | NS |
| Extraglandular manifestations* | ||||
| during disease course | 7 (24) | 6 (21) | 6 (21) | NS |
| Autoantibodies | ||||
| IgM RF | 12 (48) | 14 (48) | 15 (52) | NS |
| ANA | 27 (93) | 26 (90) | 26 (90) | NS |
| Ro (SS-A) | 15 (52) | 14 (48) | 15 (52) | NS |
| La (SS-B) | 8 (28) | 7 (24) | 10 (31) | NS |
| Average focus score (/4 mm2) | 1–8 | 1–7 | 1–8 | |